The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic revi... by Shubin Chen, Wanying Mo, Wei Jiang, Shaozhang Zhou, Haijie Gan, Qitao Yu

Get full text